# SOLENO THERAPEUTICS INC

SOLENO THERAPEUTICS INC is an Asset Manager based in United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** United States
- **Region:** North America
- **Address:** United States
- **Assets under management:** Undisclosed
- **Website:** https://solenotherapeutics.com

## Regulatory record

- **Reports private funds:** No

## About

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.

## Sectors

- Biotech
- Pharmaceuticals
- Therapeutics

## Questions

### What drug candidate is Soleno currently developing?

Soleno's lead asset is DCCR (diazoxide choline), a once-daily oral tablet for Prader-Willi syndrome (PWS), a rare genetic disorder. DCCR is intended to treat hyperphagia (extreme hunger) and other symptoms of PWS (per company Phase 3 data, 2024). The company has completed pivotal trials and is preparing for FDA submission.

### Does Soleno Therapeutics invest in other companies or funds?

No public disclosures indicate that Soleno makes external investments in other companies or funds. Its capital is allocated solely to internal R&D and clinical development of DCCR. The firm is a drug developer, not an investment vehicle.

## Related profiles

- [ALSOK Co Ltd.](https://altss.com/profile/alsok-co-ltdadr)
- [Wisconsin Electric Power Co](https://altss.com/profile/wisconsin-electric-power-co)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/soleno-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology